Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has reported earnings for its third fiscal quarter (ending September 30) of $4.05 versus $4.01 for the same period a year ago — an increase of 1%. For the latest four quarters through September 30, E.P.S. were $-1.85 versus $13.48 for the same period a year ago — a decline of -114%.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock rose modestly by 0.4% on 11/4/24. The stock closed at $472.80. Moreover, this advance was accompanied by above average trading volume at 121% of normal. Relative to the market the stock has been strong over the last nine months but has declined -1.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, VRTX is expected to continue to be an important Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Vertex Pharmaceuticals has a neutral Appreciation Score of 51 but a good Power Rating of 71, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment